Cancer's ability to colonize bones represents one of oncology's most persistent challenges, transforming skeletal tissue into sanctuaries where tumors evade treatment and cause debilitating complications. Understanding why bone metastases resist standard therapies while causing severe pain and fractures has become critical as cancer survivorship extends and skeletal involvement becomes increasingly common across tumor types.
This comprehensive analysis reveals that specialized immune cells called myeloid cells undergo dramatic reprogramming within bone tissue, essentially switching sides to support cancer growth rather than fighting it. Five distinct molecular pathways orchestrate this betrayal: RANKL promotes bone destruction, TGF-β suppresses anti-tumor immunity, CSF-1/CSF-1R recruits supportive macrophages, CCL2/CCR2 attracts additional immune accomplices, and Siglec sialoglycan interactions further dampen immune responses. These reprogrammed cells—including tumor-associated macrophages, myeloid-derived suppressor cells, neutrophils, and corrupted dendritic cells—collaborate with bone-remodeling osteoclasts to create an environment where cancer thrives.
This mechanistic understanding explains why checkpoint immunotherapies, successful in many cancers, largely fail in bone-dominant disease. The bone microenvironment actively subverts the immune awakening these drugs attempt to trigger. However, emerging combination strategies show promise by simultaneously targeting multiple pathways—pairing immune checkpoint blockade with bone-modifying agents and TGF-β inhibitors. While clinical translation faces hurdles including tumor heterogeneity and inadequate biomarkers, these insights suggest that defeating bone metastases requires coordinated attacks on both the cancer cells and their corrupted immune ecosystem, potentially transforming outcomes for patients facing this devastating complication.